UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

FORM 10-Q

☑ QUARTERLY REPORT PURSUAN QUARTERLY PERIOD ENDED MA	NT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT ARCH 31, 2017	Γ OF 1934 FOR THE
	OR	
☐ TRANSITION REPORT PURSUAN TRANSITION PERIOD FROM	NT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT	T OF 1934 FOR THE
Commission File Number: 001-12421		
	NU SKIN. DISCOVER THE BEST YOU!	
	NU SKIN ENTERPRISES, INC.	
	(Exact name of registrant as specified in its charter)	
Delaware (State or other jurisdiction of incorporation or organization)	75 WEST CENTER STREET PROVO, UTAH 84601 (Address of principal executive offices, including zip code)	87-0565309 (IRS Employer Identification No.)
	(801) 345-1000 (Registrant's telephone number, including area code)	
during the preceding 12 months (or for sucl requirements for the past 90 days. Yes Indicate by check mark whether the registra	ant has submitted electronically and posted on its corporate Web site, if any, ev 105 of Regulation S-T during the preceding 12 months (or for such shorter peri	as been subject to such filing very Interactive Date File required to
	ant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smal of "large accelerated filer," "accelerated filer," "smaller reporting company," a	
Large accelerated filer \square	Accelerated filer $\ \square$	
Non-accelerated filer □ (Do not check if a smaller reporting compared)	• /	
	Emerging growth company \Box	
	by check mark if the registrant has elected not to use the extended transition perioded pursuant to Section 13(a) of the Exchange Act. \Box	riod for complying with any new or
Indicate by check mark whether the registra	ant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes $\ \Box$	l No ☑
As of April 30, 2017, 52,840,388 shares of	the registrant's Class A common stock, \$.001 par value per share, were outstar	nding.

NU SKIN ENTERPRISES, INC.

QUARTERLY REPORT ON FORM 10-Q – FIRST QUARTER 2017

TABLE OF CONTENTS

			Page
Part I.	Financial Info	rmation	•
	Item 1.	<u>Financial Statements (Unaudited):</u>	
		Consolidated Balance Sheets	1
		Consolidated Statements of Income	2
		Consolidated Statements of Comprehensive Income	3
		Consolidated Statements of Cash Flows	4
		Notes to Consolidated Financial Statements	5
	Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	19
	Item 3.	Quantitative and Qualitative Disclosures about Market Risk	28
	Item 4.	Controls and Procedures	28
Part II.	Other Informa	ation	
1 a1 t 11.	Item 1.	Legal Proceedings	28
	Item 1A.	Risk Factors	29
	Item 2.	<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	30
	Item 3.	Defaults Upon Senior Securities	31
	Item 4.	Mine Safety Disclosures	31
	Item 5.	Other Information	31
	Item 6.	Exhibits	31
	Signature		33

In this Quarterly Report on Form 10-Q, references to "dollars" and "\$" are to United States ("U.S.") dollars.

Nu Skin, Pharmanex, and ageLOC are our trademarks. The italicized product names used in this Quarterly Report on Form 10-Q are product names and also, in certain cases, our trademarks.

PART I. FINANCIAL INFORMATION

ITEM 1. <u>FINANCIAL STATEMENTS</u>

NU SKIN ENTERPRISES, INC.

Consolidated Balance Sheets (Unaudited)

(U.S. dollars in thousands)

ASSETS	March 31, 2017		December 31, 2016	
Current assets:				
Cash and cash equivalents	\$	335,578	\$	357,246
Current investments		11,759		10,880
Accounts receivable		28,838		31,199
Inventories, net		251,947		249,936
Prepaid expenses and other		77,717		65,076
		705,839		714,337
Property and equipment, net		450,607		444,732
Goodwill		114,954		114,954
Other intangible assets, net		61,678		63,553
Other assets	_	161,338	_	136,469
Total assets	\$	1,494,416	\$	1,474,045
LIABILITIES AND STOCKHOLDERS' EQUITY				
Current liabilities:	_		_	
Accounts payable	\$	42,076	\$	41,261
Accrued expenses		253,359		275,023
Current portion of long-term debt		99,482		82,727
		394,917		399,011
Long-term debt		329,001		334,165
Other liabilities		82,913		76,799
Total liabilities		806,831		809,975
Commitments and contingencies (Note 11)				
Stockholders' equity:				
Class A common stock – 500 million shares authorized, \$.001 par value, 90.6 million shares issued		91		91
Additional paid-in capital		449,762		439,635
Treasury stock, at cost – 37.7 million and 38.0 million shares		(1,251,788)		(1,250,123)
Accumulated other comprehensive loss		(74,771)		(84,122)
Retained earnings		1,564,291		1,558,589
	_	687,585	_	664,070
Total liabilities and stockholders' equity	\$	1,494,416	\$	1,474,045

	Three Months Ended March 31,		
	2017		2016
Revenue	\$ 499,099	\$	471,831
Cost of sales	 111,266		137,869
Gross profit	 387,833		333,962
Operating expenses:			
Selling expenses	209,008		195,559
General and administrative expenses	 132,563		130,254
Total operating expenses	 341,571		325,813
Operating income	46,262		8,149
Other income (expense), net	 (4,567)		(2,863)
Income before provision for income taxes	41,695		5,286
Provision for income taxes	 14,206		1,970
Net income	\$ 27,489	\$	3,316
Net income per share (Note 2):			
Basic	\$ 0.52	\$	0.06
Diluted	\$ 0.51	\$	0.06
Weighted-average common shares outstanding (000s):			
Basic	52,678		55,955
Diluted	54,057		56,411

NU SKIN ENTERPRISES, INC.

Consolidated Statements of Comprehensive Income (Unaudited)

(U.S. dollars in thousands)

	Three Months Ende March 31,			
		2017		2016
Net income	\$	27,489	\$	3,316
Other comprehensive income, net of tax: Foreign currency translation adjustment, net of taxes of \$(222) and \$(2,451), respectively Net unrealized gains (losses) on foreign currency cash flow hedges, net of taxes of \$213 and \$931, respectively Reclassification adjustment for realized losses (gains) in current earnings, net of taxes of \$(24) and \$(66),		9,695 (387)		5,589 (1,690)
respectively	_	43 9,351		120 4,019
Comprehensive income	\$	36,840	\$	7,335

	Three Months Ended March 31,			
		2017		2016
Cash flows from operating activities: Net income Adjustments to reconcile net income to net cash provided by operating activities:	\$	27,489	\$	3,316
Depreciation and amortization		17,625		16,945
Equity method earnings		(104)		
Japan customs expense		`—		31,355
Foreign currency losses		791		2,411
Stock-based compensation		3,929		2,447
Deferred taxes		4,522		3,668
Changes in operating assets and liabilities:				
Accounts receivable		3,269		4,254
Inventories, net		2,340		(6,906)
Prepaid expenses and other		(12,088)		(68,479)
Other assets		(2,023)		2,361
Accounts payable		(125)		4,607
Accrued expenses		(26,282)		5,128
Other liabilities		1,984		(3,823)
Net cash provided by (used in) operating activities		21,327		(2,716)
Cash flows from investing activities:				
Purchases of property and equipment		(15,928)		(10,942)
Proceeds on investment sales		4,188		3,902
Purchases of investments		(4,716)		(4,538)
Acquisitions		_		(3,300)
Investment in equity investee		(12,600)		
Net cash used in investing activities		(29,056)		(14,878)
Cash flows from financing activities:				
Exercise of employee stock options and taxes paid related to the net shares settlement of stock awards		164		2,271
Payments on long-term debt		(17,830)		(15,308)
Payment of cash dividends		(18,987)		(19,840)
Income tax benefit of equity awards		_		3,402
Proceeds from long-term debt		25,000		23,721
Repurchases of shares of common stock		(6,816)		(20,006)
Net cash used in financing activities		(18,469)		(25,760)
Effect of exchange rate changes on cash		4,530	_	4,087
Net decrease in cash and cash equivalents		(21,668)		(39,267)
Cash and cash equivalents, beginning of period		357,246	-	289,354
Cash and cash equivalents, end of period	\$	335,578	\$	250,087

1. THE COMPANY

Nu Skin Enterprises, Inc. (the "Company") is a leading, global direct selling company that develops and distributes premium-quality, innovative personal care products and nutritional supplements that are sold worldwide under the Nu Skin and Pharmanex brands and a small number of other products and services. Over the last several years, the Company has introduced new Pharmanex nutritional supplements and Nu Skin personal care products under its *ageLOC* antiaging brand. The Company reports revenue from seven segments: Mainland China; South Korea; South Asia/Pacific, which consists of Australia, Brunei, French Polynesia, Indonesia, Malaysia, New Caledonia, New Zealand, the Philippines, Singapore, Thailand and Vietnam; Americas, which consists of the United States, Canada and Latin America; Japan; Hong Kong/Taiwan; and Europe, Middle East and Africa ("EMEA"), which consists of several markets in Europe as well as Israel, Russia, Ukraine and South Africa (the Company's subsidiaries operating in these countries in each segment are collectively referred to as the "Subsidiaries").

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. The unaudited consolidated financial statements include the accounts of the Company and its Subsidiaries. All significant intercompany accounts and transactions are eliminated in consolidation. In the opinion of management, the accompanying unaudited consolidated financial statements contain all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company's financial information as of March 31, 2017, and for the three-month periods ended March 31, 2017 and 2016. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the fiscal year. The consolidated balance sheet as of December 31, 2016 has been prepared using information from the audited financial statements at that date. For further information, refer to the consolidated financial statements and accompanying footnotes included in the Company's Annual Report on Form 10-K for the year ended December 31, 2016.

2. NET INCOME PER SHARE

Net income per share is computed based on the weighted-average number of common shares outstanding during the periods presented. Additionally, diluted earnings per share data gives effect to all potentially dilutive common shares that were outstanding during the periods presented. For the three-month periods ended March 31, 2017 and 2016, stock options of 0.8 million and 2.6 million, respectively, were excluded from the calculation of diluted earnings per share because they were anti-dilutive.

3. DIVIDENDS PER SHARE

In February 2017, the Company's board of directors declared a quarterly cash dividend of \$0.36 per share. This quarterly cash dividend of \$19.0 million was paid on March 15, 2017 to stockholders of record on February 27, 2017. In May 2017, the Company's board of directors declared a quarterly cash dividend of \$0.36 per share to be paid on June 14, 2017 to stockholders of record on May 26, 2017.

4. DERIVATIVE FINANCIAL INSTRUMENTS

The Company enters into non-designated foreign currency derivatives, primarily comprised of foreign currency forward contracts, for which hedge accounting does not apply. The changes in the fair market value of these non-designated derivatives are included in other income/expense in the Company's consolidated statements of income. The Company uses non-designated foreign currency derivatives to hedge foreign-currency-denominated intercompany transactions and to partially mitigate the impact of foreign-currency fluctuations. The fair value of the non-designated foreign currency derivatives is based on third-party quotes.

NU SKIN ENTERPRISES, INC. Notes to Consolidated Financial Statements

As of March 31, 2017, the Company did not hold any non-designated derivative contracts. As of March 31, 2016, the Company held non-designated derivative contracts with notional amounts of 500 million Japanese yen (\$4.4 million) and 5.8 billion Korean won (\$5.0 million). Gains and losses related to non-designated derivative contracts are recorded as part of Other Income (Expense).

The following table summarizes gains (losses) related to derivative instruments not designated as hedging instruments during the three-month periods ended March 31, 2017 and 2016 (U.S. dollars in thousands):

		Amount of Gain (Loss) Recognized in Income					
			Three Mon				
	Location of Gain (Loss)	March 31,					
Derivatives not designated as hedging instruments:	Recognized in Income	2017		2	016		
Foreign currency contracts	Other income (expense)	\$	(485)	\$	(4)		

The Company designates as cash-flow hedges those foreign currency forward contracts it enters to hedge forecasted intercompany transactions that are subject to foreign currency exposures. Changes in the fair value of these forward contracts designated as cash-flow hedges are recorded as a component of accumulated other comprehensive income (loss) within shareholders' equity (deficit), and are recognized in the consolidated statement of income during the period which approximates the time the hedged transaction is settled.

As of March 31, 2017, the Company held forward contracts designated as foreign currency cash flow hedges with notional amounts totaling 2.3 billion Japanese yen (\$20.6 million), compared to 3.9 billion Japanese yen and 12.0 million euros (\$34.6 million and \$13.7 million, respectively) as of March 31, 2016, to hedge forecasted foreign-currency-denominated intercompany transactions. The fair value of these hedges were \$0.3 million and \$2.0 million as of March 31, 2017 and 2016, respectively. The contracts held at March 31, 2017 have maturities through April 2018, and accordingly, all unrealized gains and losses on foreign currency cash flow hedges included in accumulated other comprehensive loss will be recognized in current earnings over the next 13 months.

The following table summarizes gains (losses) related to derivative instruments recorded in other comprehensive income (loss) during the three-month periods ended March 31, 2017 and 2016 (U.S. dollars in thousands):

	Amount of Gain (Loss) Recognized in Other Comprehensive Loss						
	Three Months Ended March 31,						
Derivatives designated as hedging instruments:		2017		2016			
Foreign currency forward contracts related to intercompany license fee, product sales, and selling expense hedges	\$	(387)	\$	(1,690)			

The following table summarizes gains (losses) relating to derivative instruments reclassified from accumulated other comprehensive loss into income during the three-month periods ended March 31, 2017 and 2016 (U.S. dollars in thousands):

Derivatives designated	Location of Gain (Loss) Reclassified from Accumulated Other	Accumulated Other Comprehensive Loss into Income Three Months Ended March 31,					
as hedging instruments:	Comprehensive Loss into Income	2017		2016			
Foreign currency forward contracts related to intercompany license							
fees and product sales hedges	Revenue	\$	(25)	\$	(78)		
Foreign currency forward contracts related to intercompany selling expense hedges	Selling expenses	\$	(41)	\$	(107)		

Amount of Gain (Loss) Reclassified from

As of March 31, 2017 and December 31, 2016, there were \$0.2 million and \$0.6 million, respectively, of unrealized gains/(losses) included in accumulated other comprehensive loss related to foreign currency cash flow hedges. The remaining \$75.0 million and \$84.7 million as of March 31, 2017 and December 31, 2016, respectively, in accumulated other comprehensive loss are related to cumulative translation adjustments. The Company assesses hedge effectiveness at least quarterly. During the three months ended March 31, 2017 and 2016, all hedges were determined to be effective.

The Company reports its derivatives at fair value as either other current assets or accrued expenses within its consolidated balance sheet. See Note 13 Fair Value.

5. REPURCHASES OF COMMON STOCK

During the three-month periods ended March 31, 2017 and 2016, the Company repurchased 0.1 million and 0.6 million shares of its Class A common stock under its open market stock repurchase plan for \$6.8 million and \$20.0 million, respectively. As of March 31, 2017, \$192.9 million was available for repurchases under the Company's open market stock repurchase plan.

6. SEGMENT INFORMATION

As a result of the Company's management changes in the first quarter of 2017, the Company concluded that the Chief Operating Decision Maker, as defined in ASC 280 is now comprised of the CEO, President and CFO. This change required the Company to reevaluate its determination of operating segments. The Company's operating segments are based on geographic regions that generate revenue and hold its long-lived assets. The Company sells and distributes its products through a global network of customers and sales leaders in approximately 50 markets. The Company has divided these markets into seven operating segments, which are the Company's reportable segments: Mainland China, Hong Kong/Taiwan, South Korea, Japan, South Asia/Pacific, Americas and EMEA. The seven reportable segments generate revenue from the sale of personal care products and nutritional supplements under the Nu Skin and Pharmanex brands, have similar business characteristics and align with how the CODM function began assessing performance and allocating resources in the first quarter of 2017.

Profitability by segment as reported under US GAAP is driven primarily by the Company's international taxation policies. Segment contribution, which is the Company's segment profitability metric presented in the table below, excludes certain intercompany charges, specifically royalties, license fees, transfer pricing, discrete charges and other miscellaneous items. These charges have been included in Corporate and other expenses. Corporate and other expenses also include costs related to the Company's executive and administrative offices, information technology, research and development, marketing and supply chain functions not recorded at the segment level.

The accounting policies of the segments are the same as those described in Note 1 – The Company. The Company evaluates the performance of its segments based on revenue and segment contribution. Each segment records direct expenses related to its employees and its operations.

Summarized financial information for the Company's reportable segments is shown in the following tables. Asset information is not reviewed or included with the Company's internal management reporting. Therefore, the Company has not disclosed asset information for each reportable segment.

Revenue by Segment

Three Months Ended
March 31

(U.S. dollars in thousands)	2017	2016	
		2016	
Mainland China \$	150,004	\$ 118,65	
South Korea	82,471	86,11	
South Asia/Pacific	69,798	63,57	
Americas	65,658	65,74	
Japan	61,156	65,09	
Hong Kong/Taiwan	35,948	40,05	
EMEA	34,064	32,58	
Total \$	499,099	\$ 471,83	

Segment Contribution

Three Months Ended

IVIACUI S				31,			
(U.S. dollars in thousands)	2017			2016			
Mainland China	\$	35,427	\$	18,301			
South Korea		24,512		24,057			
South Asia/Pacific		13,980		12,453			
Americas		10,096		10,472			
Japan		12,426		12,047			
Hong Kong/Taiwan		5,083		8,358			
EMEA		1,791		347			
Total segment contribution		103,315		86,035			
Corporate and other		(57,053)		(77,886)			
Operating income		46,262		8,149			
Other income (expense)		(4,567)		(2,863)			
Income before provision for income taxes	\$	41,695	\$	5,286			

Depreciation and Amortization

Three 1	Months	Ended
7.	Tarch 2	1

	Mai Cii 31	cii 51,			
(U.S. dollars in thousands)	201	.7	2016		
Mainland China	\$	3,971 \$	4,027		
South Korea		1,632	1,641		
South Asia/Pacific		563	563		
Americas		530	659		
Japan		880	893		
Hong Kong/Taiwan		302	564		
EMEA		272	304		
Corporate and other		9,475	8,294		
Total	\$	17,625 \$	16,945		

Capital Expenditures

Three Months Ended

	March 31,						
(U.S. dollars in thousands)		2017		2016			
Mainland China	\$	903	\$	4,900			
South Korea		448		270			
South Asia/Pacific		183		277			
Americas		251		278			
Japan		76		739			
Hong Kong/Taiwan		606		228			
EMEA		193		465			
Corporate and other		13,268		3,785			
Total	\$	15,928	\$	10,942			

Revenue by Major Market

A major market is defined as one with total revenue greater than 10% of consolidated total revenue. As shown in the revenue by segment table above, the Company identified three major markets: Mainland China, South Korea and Japan. There are approximately 50 other markets, each of which individually is less than 10%. No single customer accounted for 10% or more of net sales for the periods presented. Sales are recorded in the jurisdiction in which the transactions occurred.

Revenue by Product Line

Three Months Ended

		March 31,			
(U.S. dollars in thousands)	20)17	2016		
Nu Skin	\$	301,873 \$	289,989		
Pharmanex		196,103	180,714		
Other		1,123	1,128		
Total	\$	499,099 \$	471,831		

Long-Lived Assets by Major Market

A major market is defined as a market with long-lived assets greater than 10% of consolidated long-lived assets and also includes the Company's country of domicile (the U.S.). Long-lived assets in Mainland China consist primarily of property, plant and equipment related to manufacturing, distribution facilities and the Mainland China headquarters. Long-lived assets in the U.S. consist primarily of property, plant and equipment, including the Company's corporate offices and distribution facilities. Long-lived assets by major markets are set forth below:

(U.S. dollars in thousands)	March 31, 2017		December 2016		
United States	\$	289,228	\$	283,868	
Mainland China		95,458		97,867	
South Korea		44,280		41,545	
Japan		11,250		11,517	
All others		10,391		9,935	
Total	\$	450,607	\$	444,732	

7. GOODWILL

During the first quarter of 2017, the Company realigned its operational segments and reporting structure to reflect how the business will be managed going forward. As part of this realignment, the Company divided its single operating segment into seven geographical reporting segments. The Company's reporting units for goodwill are its operating segments, which are also its reportable segments. As a result of the segment changes, the historical goodwill of \$115.0 million was allocated to the seven reportable segments.

The following table presents goodwill allocated to the Company's reportable segments for the periods ended March 31, 2017 and December 31, 2016 (U.S. dollars in thousands):

	<u>-</u>	March 31, 2017	December 31, 2016 ⁽¹⁾		
Mainland China	\$	32,179	\$	32,179	
South Korea		29,261		29,261	
South Asia/Pacific		18,537		18,537	
Americas		9,449		9,449	
Japan		16,019		16,019	
Hong Kong/Taiwan		6,634		6,634	
EMEA		2,875		2,875	
Total	\$	114,954	\$	114,954	

⁽¹⁾ Goodwill was recast to reflect current period presentation by geographic region at December 31, 2016.

8. INVENTORY

Inventories consist of the following (U.S. dollars in thousands):

		March 31, 2017	December 31, 2016		
Raw materials	\$	104,177	\$	108,276	
Finished goods	<u></u>	147,770	Φ.	141,660	
	<u>\$</u>	251,947	\$	249,936	

9. DEFERRED TAX ASSETS AND LIABILITIES

The Company accounts for income taxes in accordance with the Income Taxes Topic of the Financial Accounting Standards Codification. These standards establish financial accounting and reporting standards for the effects of income taxes that result from an enterprise's activities during the current and preceding years. The Company takes an asset and liability approach for financial accounting and reporting of income taxes. The Company pays income taxes in many foreign jurisdictions based on the profits realized in those jurisdictions, which can be significantly impacted by terms of intercompany transactions between the Company and its foreign affiliates. Deferred tax assets and liabilities are created in this process. The Company has netted these deferred tax assets and deferred tax liabilities by jurisdiction. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be ultimately realized. As of March 31, 2017 and December 31, 2016, the Company had net deferred tax assets of \$31.7 million and \$35.1 million, respectively.

The Company evaluates its indefinite reinvestment assertions with respect to foreign earnings for each quarter. Other than earnings the Company intends to reinvest indefinitely, the Company accrues for the U.S. federal and state income taxes applicable to the earnings. For all foreign earnings, the Company accrues the applicable foreign income taxes. The Company intends to utilize the offshore earnings to fund foreign investments, specifically capital expenditures. Undistributed earnings that the Company has indefinitely reinvested, for which no federal or state income taxes in the U.S. have been provided, aggregate to \$70.0 million as of December 31, 2016. If the amount designated as indefinitely reinvested as of December 31, 2016 was repatriated to the United States, the amount of incremental taxes would be approximately \$7.6 million.

10. UNCERTAIN TAX POSITIONS

The Company files income tax returns in the U.S. federal jurisdiction, and in various state and foreign jurisdictions. The Company is no longer subject to tax examinations from the IRS for all years for which tax returns have been filed before 2011. With a few exceptions, the Company is no longer subject to state and local income tax examination by tax authorities for the years before 2011. In 2009, the Company entered into a voluntary program with the IRS called Compliance Assurance Process ("CAP"). The objective of CAP is to contemporaneously work with the IRS to achieve federal tax compliance and resolve all or most of the issues prior to filing of the tax return. The Company has elected to participate in the CAP program for 2017 and may elect to continue participating in CAP for future tax years; the Company may withdraw from the program at any time. In major foreign jurisdictions, the Company is generally no longer subject to income tax examinations for years before 2010. However, statutes in certain countries may be as long as ten years for transfer pricing related issues. Along with the IRS examination of 2011, the Company is currently under examination in certain foreign jurisdictions; however, the outcomes of those reviews are not yet determinable.

The Company's unrecognized tax benefits relate to multiple foreign and domestic jurisdictions. There are potential changes in unrecognized tax benefits from the multiple jurisdictions in which the Company operates, as well as the expiration of various statutes of limitation and possible completion of tax examinations; however, the Company does not anticipate that total unrecognized tax benefits will significantly change over the next 12 months.

11. COMMITMENTS AND CONTINGENCIES

The Company is subject to government regulations pertaining to product formulation, labeling and packaging, product claims and advertising, and the Company's direct selling system. The Company is also subject to the jurisdiction of numerous foreign tax and customs authorities. Any assertions or determination that either the Company or the Company's sales force is not in compliance with existing statutes, laws, rules or regulations could have a material adverse effect on the Company's operations. In addition, in any country or jurisdiction, the adoption of new statutes, laws, rules or regulations or changes in the interpretation of existing statutes, laws, rules or regulations could have a material adverse effect on the Company and its operations. Although management believes that the Company is in compliance in all material respects with the statutes, laws, rules and regulations of every jurisdiction in which it operates, no assurance can be given that the Company's compliance with applicable statutes, laws, rules and regulations will not be challenged by foreign authorities or that such challenges will not have a material adverse effect on the Company's financial position, results of operations or cash flows. The Company and its Subsidiaries are defendants in litigation, investigations and other proceedings involving various matters. In the opinion of the Company's management, based upon advice of its counsel handling such litigation, investigations and other proceedings, adverse outcomes, if any, will not likely result in a material effect on the Company's consolidated financial condition, results of operations or cash flows.

The Company is subject to regular audits by federal, state and foreign tax authorities. These audits may result in additional tax liabilities. The Company believes it has appropriately provided for income taxes for all years. Several factors drive the calculation of its tax reserves. Some of these factors include: (i) the expiration of various statutes of limitations; (ii) changes in tax law and regulations; (iii) issuance of tax rulings; and (iv) settlements with tax authorities. Changes in any of these factors may result in adjustments to the Company's reserves, which would impact its reported financial results.

12. DEBT

Credit Agreement

On October 9, 2014, the Company entered into a Credit Agreement (the "Credit Agreement") with various financial institutions, and Bank of America, N.A. as administrative agent. The Credit Agreement provides for a \$127.5 million term loan facility, a 6.6 billion Japanese yen term loan facility and a \$187.5 million revolving credit facility, each with a term of five years. On October 10, 2014, the Company drew the full amount of the term loan facilities, and as of December 31, 2015 and 2016, the Company had an outstanding balance of \$47.5 million on the revolving credit facility. Any additional amounts drawn under the revolving credit facility will bear interest at rates that will be determined in accordance with the Credit Agreement. The Credit Agreement requires that the Company maintains a consolidated leverage ratio not exceeding 2.25 to 1.00 and a consolidated interest coverage ratio of no less than 3.00 to 1.00. The Company believes these covenants provide it with greater flexibility to pay dividends and repurchase stock. The Company is in compliance with its debt covenants.

Convertible Note

On June 16, 2016, the Company issued \$210.0 million of convertible senior notes (the "Convertible Notes") in a private offering to a Chinese investor (the "Holder"). The Convertible Notes are senior unsecured obligations which will rank equal in right of payment to all senior unsecured indebtedness of the Company, and will rank senior in right of payment to any indebtedness that is contractually subordinated to the Convertible Notes. Interest on the Convertible Notes is payable semiannually in arrears on June 15 and December 15 of each year at a rate of 4.75% per annum.

The Convertible Notes mature on June 15, 2020, unless repurchased or converted prior to maturity. Prior to the stated maturity date, the Company may, at its option, redeem all or part of the Convertible Notes at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, provided that its common stock share price is equal to or exceeds 180% of the applicable conversion price for 20 or more trading days (including the final three trading days) in the 30 consecutive trading days prior to the Company's exercise of such redemption right. The Holder of the Convertible Notes may, at its option, cause the Company to repurchase all of such Holder's Convertible Notes or any portion thereof that is equal to \$1,000 in principal amount or multiples of \$1,000 upon a change in control or a termination of trading of the Company's common stock, as those terms are defined in the indenture governing the Convertible Notes. In addition, each holder of the Convertible Notes shall have the right, at such holder's option, to convert all or any portion thereof that is equal to \$1,000 in principal amount or multiples of \$1,000 at any time beginning six calendar months following June 16, 2016, at the then-applicable conversion rate. Upon conversion by the Holder, the Convertible Notes will be settled in cash with respect to principal and any accrued and unpaid interest to such date and in the Company's common shares with respect to any additional amounts, based on the applicable conversion rate at such time. The Convertible Notes had an initial conversion rate of 21.5054 common shares per \$1,000 principal amount of the Convertible Notes (which is equal to an initial conversion price of approximately \$46.50 per common share). Throughout the term of the Convertible Notes, the conversion rate may be adjusted upon the occurrence of certain specified events.

Of the \$210.0 million in proceeds received from the issuance of the Convertible Notes, \$199.1 million was allocated to long-term debt (the "Liability Component") and \$10.9 million was allocated to additional paid-in capital (the "Equity Component") within the Company's consolidated balance sheet. The Liability Component was calculated by measuring the fair value of a similar debt instrument that does not have an associated conversion feature. The amount allocated to the Equity Component, which represents the conversion option, was calculated by deducting the fair value of the Liability Component from the par value of the Convertible Notes. The Company determined that the conversion option does not require separate accounting treatment as a derivative instrument because it is both indexed to the Company's own stock and would be classified in stockholders' equity if freestanding. The Equity Component will not be remeasured as long as it continues to meet the conditions for equity classification. The excess of the principal amount of the Liability Component over its carrying amount (the "Debt Discount") will be amortized to interest expense over the term of the Convertible Notes. As a result, the Liability Component will be accreted up to the Convertible Notes' \$210.0 million face value, resulting in additional non-cash interest expense being recognized within the Company's consolidated statement of income. The effective interest rate on the Convertible Notes is approximately 7.1% per annum.

The net carrying amount of the Liability Component is as follows (U.S. dollars in thousands):

	March 31, 2017
Principal	\$ 210,000
Unamortized debt discount (conversion option)	(9,003)
Total long-term debt, net	200,997
Unamortized debt discount (issuance costs)	(5,152)
Net carrying amount	\$ 195,845

The net carrying amount of the Liability Component was recorded to long-term debt within the Company's consolidated balance sheet.

The Company incurred approximately \$6.6 million of issuance costs related to the issuance of the Convertible Notes. Of the \$6.6 million in issuance costs incurred, \$6.3 million and \$0.3 million were recorded to deferred financing cost and additional paid-in capital, respectively, in proportion to the allocation of the proceeds of the Convertible Notes. The \$6.3 million recorded to deferred financing cost on the Company's consolidated balance sheet as a reduction of long-term debt is being amortized over the contractual term of the Convertible Notes using the effective interest method.

During the three months ended March 31, 2017, the Company recognized \$3.5 million in interest expense related to the Convertible Notes, which included \$2.5 million of contractual interest and \$1.0 million in amortization of debt issuance costs and in amortization of the Debt Discount.

The following table summarizes the Company's debt facilities as of March 31, 2017 and December 31, 2016:

S	1 3				
Facility or Arrangement	Original Principal Amount	Balance as of March 31, 2017 ⁽¹⁾ (2)	Balance as of December 31, 2016	Interest Rate	Repayment terms
Credit Agreement term loan facility:					
U.S. dollar denominated:	\$127.5 million	\$105.2 million	\$108.4 million	Variable 30 day: 3.73%	One half of the principal amount payable in increasing quarterly installments over a five-year period beginning on December 31, 2014, with the remainder payable at the end of the five-year term.
Japanese yen denominated:	6.6 billion yen	5.4 billion yen (\$48.8 million as of March 31, 2017)	5.6 billion yen (\$47.9 million as of December 31, 2016)	Variable 30 day: 2.76%	One half of the principal amount payable in increasing quarterly installments over a five-year period beginning on December 31, 2014, with the remainder payable at the end of the five-year term.
Credit Agreement revolving credit facility:					
		\$72.5 million	\$47.5 million	Variable 30 day: 3.73%	Revolving line of credit expires October 2019.
Korea subsidiary loan:	\$20.0 million	_	\$10.0 million	1.12%	Loan paid in full as of March 2017.
Japan subsidiary loan:	2.0 billion yen	1.0 billion yen (\$9.0 million as of March 31, 2017)	1.3 billion yen (\$11.4 million as of December 31, 2016)	0.66%	Payable in semi-annual installments over three years that began on January 31, 2016.
Convertible note:	\$210.0 million	\$210.0 million	\$210.0 million	4.75%	Principal amount payable on June 15, 2020.

⁽¹⁾ As of March 31, 2017, the current portion of the Company's debt (i.e. becoming due in the next 12 months) included \$14.3 million of the balance of its U.S. dollar denominated debt under the Credit Agreement facility, \$6.7 million of the balance of its Japanese yen-denominated debt under the Credit Agreement facility and \$6.0 million of the Japan subsidiary loan. The Company has classified the \$72.5 million borrowed under the revolving line of credit as short term because it is the Company's intention to use the line of credit to borrow and pay back funds over short periods of time.

⁽²⁾ The carrying value of the debt reflects the amounts stated in the above table less a debt discount of \$11.9 million and debt issuance costs of \$5.2 million (consisting of \$14.2 million related to the Convertible Note and \$2.9 million related to the credit agreement), which is not reflected in this table.

NU SKIN ENTERPRISES, INC. Notes to Consolidated Financial Statements

13. FAIR VALUE

The carrying value of financial instruments including cash and cash equivalents, accounts receivable and accounts payable approximate fair values due to the short-term nature of these instruments. The Company's current investments as of March 31, 2017 include certificates of deposits and pre-refunded municipal bonds that are classified by management as held-to-maturity as the Company had the positive intent and ability to hold to maturity. The carrying value of these current investments approximate fair values due to the short-term nature of these instruments. The Company has classified these instruments as Level 2 in the fair value hierarchy. Fair value estimates are made at a specific point in time, based on relevant market information.

The FASB Codification defines fair value as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. On a quarterly basis, the Company measures at fair value certain financial assets, including cash equivalents. Accounting standards specify a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect data obtained from independent sources, while unobservable inputs reflect the Company's market assumptions. These two types of inputs have created the following fair-value hierarchy:

- Level 1 quoted prices in active markets for identical assets or liabilities;
- Level 2 inputs, other than the quoted prices in active markets, that are observable either directly or indirectly;
- Level 3 unobservable inputs based on the Company's own assumptions.

Accounting standards permit companies, at their option, to measure many financial instruments and certain other items at fair value. The Company has elected not to apply the fair value option to existing eligible items.

The following tables present the fair value hierarchy for those assets and liabilities measured at fair value on a recurring basis (U.S. dollars in thousands):

	Fair Value at March 31, 2017							
		Level 1		Level 2	_	Level 3		Total
Financial assets (liabilities):								
Cash equivalents and current investments	\$	37,947	\$	_	\$	_	\$	37,947
Other long-term assets		3,557		_		_		3,557
Forward contracts		_		339		_		339
Life insurance contracts		_				34,024		34,024
Total	\$	41,504	\$	339	\$	34,024	\$	75,867

	Fair Value at December 31, 2016							
		Level 1	_	Level 2		Level 3	_	Total
Financial assets (liabilities):								
Cash equivalents and current investments	\$	50,307	\$	_	\$	_	\$	50,307
Other long-term assets		2,782		_		_		2,782
Forward contracts		_		1,371		_		1,371
Life insurance contracts		_		_		32,286		32,286
Total	\$	53,089	\$	1,371	\$	32,286	\$	86,746

The following table provides a summary of changes in fair value of the Company's Level 3 marketable securities (U.S. dollars in thousands):

Life Insurance Contracts

Beginning balance at January 1, 2017	\$ 32,286
Actual return on plan assets:	
Relating to assets still held at the reporting date	1,535
Purchases and issuances	314
Sales and settlements	(111)
Transfers into Level 3	_
Ending balance at March 31, 2017	\$ 34,024

14. ACCOUNTING PRONOUNCEMENTS

In May 2014, the FASB issued ASU No. 2014-09, *Revenue from Contracts with Customers (Topic 606)*. The new revenue recognition standard provides a five-step analysis of transactions to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This ASU is effective for annual periods beginning after December 15, 2017. As the Company evaluates the impact of this ASU, the more significant changes that the Company has identified relate to the current method of accruing its loyalty points program from a cost provision method to a deferred revenue method in accordance with the new guidance. The Company is continuing to evaluate the impact this ASU, and related amendments and interpretive guidance, will have on its consolidated financial statements. The Company plans to adopt this ASU beginning in the first quarter of 2018 with a cumulative adjustment to retained earnings as opposed to retrospectively adjusting prior periods.

NU SKIN ENTERPRISES, INC. Notes to Consolidated Financial Statements

In July 2015, the FASB issued ASU 2015-11, *Inventory (Topic 330): Simplifying the Measurement of Inventory*. This guidance requires an entity to measure inventory at the lower of cost and net realizable value, rather than at the lower of cost or market. This ASU was effective for the Company beginning on January 1, 2017. The adoption of this guidance did not have a significant impact on the Company's consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, *Leases (Subtopic 842)*. ASU 2016-02 will require companies to recognize lease assets and lease liabilities on the balance sheet and disclose key information about leasing arrangements. For public companies, this standard is effective for annual reporting periods beginning after December 15, 2018, and early adoption is permitted. The Company is currently evaluating the impact of this standard on its consolidated financial position, results of operations, and cash flows.

In March 2016, the FASB issued ASU 2016-09, *Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.* The objective of this update was to simplify several aspects of the accounting for employee share-based payment transactions, including accounting for income taxes related to share-based compensation, the related classification in the statement of cash-flows, and accounting for share award forfeitures. This ASU was effective for the Company beginning on January 1, 2017. As required by the adoption of this new guidance, the Company recognized excess tax benefits of \$0.8 million in the provision for income taxes as a discrete item during the quarter ended March 31, 2017. Prior to January 1, 2017, excess tax benefits were recognized in equity. As permitted, the Company elected to classify excess tax benefits as an operating activity in the Statement of Cash Flows instead of as a financing activity on a prospective basis and did not retroactively adjust prior periods. As also permitted by the new guidance, beginning January 1, 2017 the Company has elected to account for share award forfeitures as they occur. Previously, share-based compensation expense was recorded net of estimated forfeitures. A cumulative adjustment of \$2.8 million was recorded to retained earnings and additional paid-in capital as of January 1, 2017. Prior periods were not retroactively adjusted.

In the second half of 2016, the FASB issued ASU Nos. 2016-15, *Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments*, and 2016-18, *Statement of Cash Flows (Topic 230): Restricted Cash*. The objective of these updates is to reduce the diversity in practice in the classification of certain cash receipts and cash payments, and the presentation of restricted cash within an entity's statement of cash flows, respectively. These ASUs are effective for interim and annual fiscal periods beginning after December 15, 2017. Early adoption is permitted. The adoption of this guidance is not expected to have a material impact on the Company's consolidated financial statements.

In January 2017, the FASB issued ASU 2017-01, *Business Combinations (Topic 805): Clarifying the Definition of a* Business. This guidance revises the definition of a business as it relates to acquisitions, disposals, goodwill impairments and consolidations. This ASU is effective for annual periods beginning after December 15, 2017. Early adoption is permitted. The adoption of this guidance is not expected to have a material impact on the Company's consolidated financial statements.

In January 2017, the FASB issued ASU 2017-04, *Intangibles – Goodwill and Other (Topic 350)*: Simplifying the Test for Goodwill Impairment. This guidance simplifies the required test of goodwill for impairment by eliminating Step 2 from the goodwill impairment test. If a company determines in Step 1 of the goodwill impairment test that the carrying value of goodwill is less than the fair value, an impairment in that amount should be recorded to the income statement, rather than proceeding to Step 2. This ASU is effective for interim and annual impairment tests in fiscal years beginning after December 15, 2019. Early adoption is permitted. The adoption of this guidance is not expected to have a material impact on the Company's consolidated financial statements.

NU SKIN ENTERPRISES, INC. Notes to Consolidated Financial Statements

15. COST OF SALES

In April 2017, the Tokyo High Court issued a ruling on a dispute between the Company and the customs authorities in Japan. The High Court affirmed the Tokyo District Court's February 2016 decision upholding previous customs assessments related to the importation of several of the Company's products into Japan during 2010. The High Court's decision applies only to imports that occurred during 2010; the Company's appeal regarding imports during the other time periods in the dispute is still pending with the High Court. The Company intends to appeal the High Court's decision to the Japan Supreme Court.

As previously disclosed, the Company already recorded a charge of \$31.4 million to cost of sales in the first quarter of 2016, when the District Court issued its decision. This was a non-cash item because the Company was previously required to pay the assessments. This charge represents the full amount that was disputed, including assessments for the period of October 2006 through September 2009 in connection with post-importation audits, as well as the disputed portion of our import duties from October 2009 to the date of the District Court's decision.

16. ACQUISITION AND INVESTMENT IN EQUITY INVESTEE

Vertical Eden, LLC

In the first quarter of 2016, the Company purchased 70% of Vertical Eden, LLC, an early-stage company in the warehouse growing market, based in Alpine, Utah, for \$3.3 million in cash and contingent consideration valued at \$1.5 million. The purchase of Vertical Eden includes specialized technology in remote programming and management of the entire crop growing cycle. As a result of this acquisition, the Company has recorded approximately \$4.4 million of intangible assets which are being amortized over the useful lives of 3 to 7 years. The Company has also recorded \$2.5 million of goodwill. Due to the insignificance of the transaction to the Company's consolidated financial statements, the Company has not separately presented the \$2.1 million non-controlling interest related to this acquisition, but has included it in other liabilities and has included the net income (loss) attributable to the non-controlling interest in other income (expense).

Treviso, LLC

On February 28, 2017, the Company purchased a 35% membership interest in Treviso, LLC, which owns a manufacturing company, for a purchase price of \$21.0 million and a possible earnout of \$1.0 million. The purchase price included \$12.6 million in cash and \$8.4 million in the Company's stock (169,560 shares based on the closing stock price of \$49.54 per share on February 28, 2017).

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This quarterly report on Form 10-Q (this "Quarterly Report") contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that represent our current expectations and beliefs. All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws and include, but are not limited to, statements of management's expectations regarding our performance, initiatives, strategies, product introductions and offerings, growth, opportunities and risks; statements of projections regarding future sales, expenses, operating results, taxes and duties, capital expenditures, sources and uses of cash, foreign currency fluctuations or devaluations, and other financial items; statements of management's expectations and beliefs regarding our markets; statements regarding the payment of future dividends and stock repurchases; statements regarding the outcome of litigation, audits or investigations; accounting estimates and assumptions; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as "believe," "expect," "project," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "could," "may," "might," the negative of these words and other similar words. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. We caution and advise readers that these statements are based on assumptions that may not be realized and involve risks and uncertainties that could cause actual results to differ materially from the expectations and beliefs contained herein. For a summary of these risks, see the risk factors included in our Annual Report on Form 10-K for the year ended December 31, 2016 and in our subse

The following Management's Discussion and Analysis should be read in conjunction with our consolidated financial statements and related notes and Management's Discussion and Analysis included in our Annual Report on Form 10-K for the year ended December 31, 2016, and our other reports filed with the Securities and Exchange Commission through the date of this report.

Overview

Revenue for the three-month period ended March 31, 2017 increased 6% to \$499.1 million when compared to the same prior-year period, with foreign currency fluctuations negatively impacting revenue approximately 1%. Sales Leaders decreased 1% and Customers increased 2% compared to the prior-year period.

Our revenue for the first quarter of 2017 reflects continued growth in Mainland China, our largest segment by revenue, where revenue increased 26% over the first quarter of 2016. We also continue to see success in Sales Leader social media initiatives, especially in certain markets of our South Asia/Pacific, Americas and EMEA segments.

Earnings per share for the first quarter of 2017 were \$0.51 compared to \$0.06 in the prior-year period, or \$0.42 in the prior-year period excluding a non-cash expense of \$31.4 million associated with the February 2016 Japan customs ruling that is discussed in Note 15 to the consolidated financial statements contained in this report. Excluding the Japan customs expense, the increase in earnings per share primarily reflects the increased revenue in 2017 and lower weighted-average shares outstanding in 2017. Earnings per share excluding Japan customs expense is a non-GAAP financial measure. See "Non-GAAP Financial Measures." below.

We anticipate difficult year-over-year comparisons in the second and third quarters of 2017, as limited-time offers in the second and third quarters of 2016 generated approximately \$106 million and \$56 million in sales, respectively. This includes approximately \$65 million generated by a limited-time offer of our *ageLOC Me* customized skin care system in our Mainland China segment and approximately \$35 million generated by a limited-time offer of our *ageLOC Youth* nutritional supplement in our South Asia/Pacific segment during the second quarter of 2016, and approximately \$49 million generated by a limited-time offer of a local variation of *ageLOC Youth* in our South Korea segment during the third quarter of 2016.

Segment Results

Effective as of the first quarter of 2017, we report our business in seven segments to reflect our current management approach. The following table sets forth revenue for the three-month periods ended March 31, 2017 and 2016 for each of our reportable segments (U.S. dollars in thousands):

Three Months Ended March 31,

	2017 2016					
			2016		Change	
Mainland China	\$	150,004	\$	118,655	26%	
South Korea		82,471		86,118	(4%)	
South Asia/Pacific		69,798		63,578	10%	
Americas		65,658		65,748	_	
Japan		61,156		65,091	(6%)	
Hong Kong/Taiwan		35,948		40,056	(10%)	
EMEA		34,064		32,585	5%	
Total	\$	499,099	\$	471,831	6%	

The table below sets forth segment contribution for the three-month periods ended March 31, 2017 and 2016 for each of our reportable segments (U.S. dollars in thousands). Segment contribution excludes certain intercompany charges, specifically royalties, license fees, transfer pricing and other miscellaneous items. We use segment contribution to measure the portion of profitability that the segment managers have the ability to control for their respective segments. For additional information regarding our segments and the calculation of segment contribution, see Note 6 to the consolidated financial statements contained in this report.

Three Months Ended March 31,

	2017	2016	Change
Mainland China	\$ 35,427	\$ 18,301	94%
South Korea	24,512	24,057	2%
South Asia/Pacific	13,980	12,453	12%
Americas	10,096	10,472	(4%)
Japan	12,426	12,047	3%
Hong Kong/Taiwan	5,083	8,358	(39%)
EMEA	1,791	347	416%

The following table provides information concerning the number of Customers and Sales Leaders as of March 31, 2017 and 2016. "Customers" are persons who have purchased products directly from the Company during the three months ended as of the date indicated. "Sales Leaders" are independent distributors, and sales employees and independent marketers in China, who achieve certain qualification requirements.

	As of Marc	h 31, 2017	As of March	n 31, 2016	
Region:	Customers	Sales Leaders	Customers	Sales Leaders	
Mainland China	176.000	10 100	142,000	16,000	
	-,	19,100	142,000	16,900	
South Korea	189,000	8,000	208,000	8,800	
South Asia/Pacific	116,000	6,900	110,000	6,800	
Americas	172,000	6,200	164,000	6,900	
Japan	132,000	6,400	145,000	7,000	
Hong Kong/Taiwan	70,000	3,900	77,000	4,800	
EMEA	125,000	4,100	112,000	3,800	
Total	980,000	54,600	958,000	55,000	

Following is a narrative discussion of our results in each segment, which supplements the tables above.

<u>Mainland China</u>. Foreign currency fluctuations negatively impacted revenue 7% in Mainland China during the three-month period ended March 31, 2017 compared to the prior-year period. Sales Leaders and Customers in Mainland China increased 13% and 24%, respectively, compared to the prior-year quarter.

We sold *ageLOC Me* on a limited basis during March 2017, with general availability beginning in April 2017. The increases in our revenue, Sales Leaders and Customers reflect favorable responses to our sales compensation and promotional incentives in this market, including the limited introduction of *ageLOC Me*.

The increase in segment contribution primarily reflects higher revenue in 2017 while the segment's general and administrative expenses remained relatively stable.

<u>South Korea</u>. Foreign currency fluctuations positively impacted revenue 4% in South Korea during the three-month period ended March 31, 2017 compared to the prior-year period. Sales Leaders and Customers in South Korea each decreased 9% compared to the prior-year period. We believe the decline in revenue was driven by the reduction in Sales Leaders, as our initiatives did not generate significant Sales Leader activity. We also believe the political and economic environment in South Korea is negatively impacting our performance in this market.

<u>South Asia/Pacific</u>. Foreign currency fluctuations negatively impacted revenue 1% in our South Asia/Pacific segment during the three-month period ended March 31, 2017 compared to the prior-year period. Sales Leaders and Customers in the segment increased 2% and 6%, respectively, compared to the prior year.

We made *ageLOC Me* generally available for purchase in certain markets of this region during the first quarter of 2017. We believe the increases in revenue, Sales Leaders and Customers reflect favorable responses by Sales Leaders to the *ageLOC Me* launch and promotional incentives, as well as successful Sales Leader social media initiatives in certain markets of the region.

The increase in segment contribution primarily reflects higher revenue in 2017, with expenses increasing approximately proportionally.

Americas. Foreign currency fluctuations impacted revenue less than 1% in the Americas segment during the three-month period ended March 31, 2017 compared to the prior-year period. Sales Leaders decreased 10% and Customers increased 5% in the Americas segment compared to the prior-year period. We believe our business in this segment is beginning to stabilize after several quarters of softness. Our revenue in the United States in the first quarter of 2017 increased 4% over the prior-year period. This increase was offset by declines in Canada and our closing of business operations in Venezuela in the third quarter of 2016.

<u>Japan</u>. Foreign currency fluctuations positively impacted revenue 1% in Japan during the three-month period ended March 31, 2017 compared to the prior-year period. Sales Leaders and Customers in Japan each decreased 9% compared to the prior-year period. The declines in revenue, Sales Leaders and Customers continued to reflect a challenging regulatory environment and softness in this market.

<u>Hong Kong/Taiwan</u>. Foreign currency fluctuations positively impacted revenue 3% in our Hong Kong/Taiwan segment during the three-month period ended March 31, 2017 compared to the prior-year period. Sales Leaders and Customers in the segment decreased 19% and 9%, respectively, compared to the prior-year period. We believe the decline in revenue was driven by the significant reduction in Sales Leaders as fewer people were selling our products.

The decrease in segment contribution reflects lower revenue in 2017, with selling expenses remaining relatively even and general and administrative expenses increasing due in part to higher labor expenses from hiring additional personnel. Our selling expenses for the quarter and the prior-year quarter are impacted by the number of Sales Leaders qualifying for promotional incentives.

<u>EMEA</u>. Foreign currency fluctuations negatively impacted revenue 2% in our EMEA segment during the three-month period ended March 31, 2017 compared to the prior-year period. Sales Leaders and Customers in the segment increased 8% and 12%, respectively, compared to the prior-year period. The growth in this segment reflects continued success of Sales Leader social media initiatives in certain markets of the region.

The increase in segment contribution reflects decreased duties and customs and decreased general and administrative expenses in the segment.

Consolidated Results

Revenue

Revenue for the three-month period ended March 31, 2017 increased 6% to \$499.1 million, compared to \$471.8 million in the prior-year period. For a discussion and analysis of this increase in revenue, see "Overview" and "Segment Results," above.

Gross profit

Gross profit as a percentage of revenue was 77.7% for the first quarter of 2017 and 70.8% in the same prior-year period. This year-over-year increase was primarily driven by the non-cash Japan customs expense of \$31.4 million in the first quarter of 2016 that is discussed in Note 15 to the consolidated financial statements contained in this report. Excluding this expense, gross profit as a percentage of revenue for the first quarter of 2016 was 77.4%. Gross profit excluding Japan customs expense is a non-GAAP financial measure. See "Non-GAAP Financial Measures," below.

Selling expenses

Selling expenses as a percentage of revenue increased to 41.9% for the three-month period ended March 31, 2016 from 41.5% for the same period in 2016.

General and administrative expenses

General and administrative expenses increased to \$132.6 million in the first quarter of 2017 compared to \$130.3 million in the prior-year period. As a percentage of revenue, general and administrative expenses decreased to 26.6% for the three-month period ended March 31, 2016 from 27.6% for the same period in 2016, reflecting higher revenue in 2017 and relatively stable general and administrative expenses.

Other income (expense), net

Other income (expense), net for the three-month period ended March 31, 2017 was \$4.6 million of expense compared to \$2.9 million of expense for the same period in 2016. The increase in expense primarily reflects an increase in interest expense due to the convertible notes that we issued in the second quarter of 2016.

Provision for income taxes

Provision for income taxes for the three-month period ended March 31, 2017 was \$14.2 million, compared to \$2.0 million for the same period in 2016. The effective tax rate was 34.1% of pre-tax income during the three-month period ended March 31, 2017 compared to 37.3% in the same prior-year period. The decrease in the effective tax rate reflects a benefit that was recorded due to the new accounting standard for stock-based compensation in the first quarter of 2017. Our effective tax rate for the first quarter of 2016 was also higher due to reduced income before taxes resulting from the Japan customs expense that is discussed in Note 15 to the consolidated financial statements contained in this report.

Net income

As a result of the foregoing factors, net income for the first quarter of 2017 was \$27.5 million compared to \$3.3 million in the prior-year period, or \$23.4 million in the prior-year period excluding Japan customs expense of \$31.4 million (\$20.1 million, net of tax). Net income excluding Japan customs expense is a non-GAAP financial measure. See "Non-GAAP Financial Measures," below.

Liquidity and Capital Resources

Historically, our principal uses of cash have included operating expenses, particularly selling expenses, and working capital (principally inventory purchases), as well as capital expenditures, stock repurchases, dividends, debt repayment and the development of operations in new markets. We have at times incurred long-term debt to fund strategic transactions and stock repurchases. We typically generate positive cash flow from operations due to favorable margins and have generally relied on cash from operations to fund operating activities. In the first quarter of 2017, we generated \$21.3 million in cash from operations compared to a net outflow of \$2.7 million in cash from operations during the prior-year period. The increase in cash flow from operations reflects fewer inventory purchases compared to the prior-year period, as our next significant product launch is scheduled for the second half of 2017. Our negative cash flow from operations in the first quarter of 2016 primarily reflected (1) the payment of significant accruals as of the end of 2015, particularly commissions based on limited-time offers during December 2015; and (2) payments to build up inventory for planned product launches in 2016.

As of March 31, 2017, working capital was \$310.9 million, compared to \$315.3 million as of December 31, 2016. Cash and cash equivalents, including current investments, as of March 31, 2017 and December 31, 2016 were \$347.3 million and \$368.1 million, respectively.

Capital expenditures in the first quarter of 2017 were \$15.9 million, and we anticipate additional capital expenditures of approximately \$45 million for the remainder of 2017. Our 2017 capital expenditures are primarily related to:

- ullet the expansion and upgrade of facilities in our various markets; and
 - purchases and expenditures for computer systems and equipment, software, and application development.

In June 2016, we issued \$210.0 million principal amount of convertible 4.75% senior notes, due 2020 (the "Convertible Notes") to Ping An ZQ China Growth Opportunity Limited ("Ping An ZQ") at face value. Net proceeds on the issuance of the Convertible Notes were \$203 million. We used the proceeds for repurchasing common stock throughout the remainder of 2016. The Convertible Notes are senior unsecured obligations of the Company and rank equal in right of payment to all senior unsecured indebtedness of the Company. Interest on the Convertible Notes is payable semiannually in cash on June 15 and December 15, and the Convertible Notes mature on June 15, 2020, subject to earlier conversion. Although the stated interest rate on the Convertible Notes is 4.75%, interest on this debt is expensed on our income statement at a rate of approximately 7.1%, reflecting the amortization of a debt discount resulting from approximately \$6.3 million in issuance costs and approximately \$10.9 million of the principal amount that is allocated to equity due to the conversion option. As of December 2016, the Convertible Notes became convertible at the holder's discretion at a conversion rate of 21.5054 per \$1,000 principal amount of Convertible Notes (which represents an initial conversion price of \$46.50 per share), in each case subject to customary anti-dilution adjustments. As of April 30, 2017, the conversion price remained at \$46.50 per share. Upon conversion, we intend to settle the Convertible Notes in cash with respect to the principal amount of Convertible Notes converted and any accrued and unpaid interest to such date, and in shares of our common stock with respect to any additional amounts.

Upon a change in control of the Company (as defined in the indenture governing the Convertible Notes) or the failure of our common stock to be listed on certain stock exchanges, the holders of the Convertible Notes may require that we repurchase all or part of the principal amount of the Convertible Notes at a purchase price equal to 108% of the principal amount plus accrued and unpaid interest. In addition, we may redeem all or part of the principal amount of the Convertible Notes, at our option, at a purchase price equal to the principal amount plus accrued and unpaid interest, provided that the closing trading price of our common stock exceeds 180% of the then-current conversion price for 20 or more trading days in the 30 consecutive trading day period preceding our exercise of this redemption right (including the last three such trading days). The Convertible Notes are subject to customary events of default, which may result in the acceleration of the maturity of the Convertible Notes.

Our Credit Agreement (the "Credit Agreement") with various financial institutions, and Bank of America, N.A. as administrative agent, provides for a \$127.5 million term loan facility, a 6.6 billion Japanese yen term loan facility and a \$187.5 million revolving credit facility, each with a term of five years ending in October 2019. The Credit Agreement requires that we maintain a consolidated leverage ratio not exceeding 2.25 to 1.00 and a consolidated interest coverage ratio of no less than 3.00 to 1.00. As of March 31, 2017, we had debt pursuant to the Credit Agreement of \$226.5 million, which includes an additional \$25.0 million borrowed under the revolving credit facility during the first quarter of 2017 for general corporate purposes. See Note 12 to the consolidated financial statements contained in this report for further information regarding the Credit Agreement and other debt.

Our board of directors has approved a stock repurchase plan authorizing us to repurchase up to \$500 million of our outstanding shares of Class A common stock on the open market or in private transactions. The repurchases are used primarily for strategic initiatives and to offset dilution from our equity incentive plans and from conversion of the Convertible Notes. During the first quarter of 2017, we repurchased approximately 0.1 million shares of Class A common stock under this plan for \$6.8 million. At March 31, 2017, \$192.9 million was available for repurchases under the stock repurchase plan.

In February 2017, our board of directors declared a quarterly cash dividend of \$0.36 per share. This quarterly cash dividend of \$19.0 million was paid March 15, 2017 to stockholders of record on February 27, 2017. In May 2017, our board of directors declared a quarterly cash dividend of \$0.36 per share to be paid on June 14, 2017 to stockholders of record on May 26, 2017. Currently, we anticipate that our board of directors will continue to declare quarterly cash dividends and that the cash flows from operations will be sufficient to fund our future dividend payments. However, the continued declaration of dividends is subject to the discretion of our board of directors and will depend upon various factors, including our net earnings, financial condition, cash requirements, future prospects and other relevant factors.

As of March 31, 2017 and December 31, 2016, we held \$347.3 million and \$368.1 million, respectively, in cash and cash equivalents, including current investments. These amounts include \$315.2 million and \$283.5 million as of March 31, 2017 and December 31, 2016, respectively, held in our operations outside of the U.S. Substantially all of our non-U.S. cash and cash equivalents are readily convertible into U.S. dollars or other currencies, subject to procedural or other requirements in certain countries as described below.

We typically fund the cash requirements of our operations in the U.S. through intercompany dividends and intercompany charges for products, use of intangible property, and corporate services. Some markets impose government-approval or other requirements for the repatriation of dividends. For example, in Mainland China, we are unable to repatriate cash from current operations in the form of dividends until we file the necessary statutory financial statements for the relevant period. As of March 31, 2017, we had \$149.2 million in cash denominated in Chinese RMB. We also have intercompany loan arrangements with some of our markets, including Mainland China, that allow us to access available cash. However, in recent months, the Chinese government has placed limits on the permitted amount of intercompany lending, which has slowed our ability to access cash in that market. We currently plan to repatriate undistributed earnings from our non-U.S. operations as necessary, considering the cash needs of our non-U.S. operations and the cash needs of our U.S. operations for dividends, stock repurchases, capital investments, debt repayment and strategic transactions. Except for partial indefinite reinvestment in two jurisdictions, we have not designated our investments as indefinitely reinvested, but rather have these funds available for our operations in the U.S. as needed. Any repatriation of non-U.S. earnings requires payment of U.S. taxes in accordance with applicable U.S. tax rules and regulations. Accordingly, we have accrued the necessary U.S. taxes related to the funds that are not indefinitely reinvested.

We currently believe that existing cash balances, future cash flows from operations and existing lines of credit will be adequate to fund our cash needs on both a short- and long-term basis. The majority of our historical expenses have been variable in nature, and as such, a potential reduction in the level of revenue would reduce our cash flow needs. In the event that our current cash balances, future cash flow from operations and current lines of credit are not sufficient to meet our obligations or strategic needs, we would consider raising additional funds in the debt or equity markets or restructuring our current debt obligations. Additionally, we would consider realigning our strategic plans, including a reduction in capital spending, stock repurchases or dividend payments.

Contingent Liabilities

Please refer to Note 11 to the consolidated financial statements contained in this report for information regarding our contingent liabilities.

Critical Accounting Policies

There were no significant changes in our critical accounting policies during the quarter ended March 31, 2017.

Seasonality and Cyclicality

In addition to general economic factors, we are impacted by seasonal factors and trends such as major cultural events and vacation patterns. For example, most Asian markets celebrate their respective local New Year in the first quarter, which generally has a negative impact on that quarter. We believe that direct selling is also generally negatively impacted during the third quarter, when many individuals, including our sales force, traditionally take vacations.

Prior to making a product generally available for purchase in a market, we typically do a promotional offering of the product, such as a preview of the product to our key Sales Leaders in the market, a limited-time offer, or other type of promotion. Sales Leader previews, limited-time offers and other promotions may generate significant activity and a high level of purchasing, which can result in a higher-than-normal increase in revenue during the quarter and can skew year-over-year and sequential comparisons.

Currency Risk and Exchange Rate Information

A majority of our revenue and many of our expenses are recognized outside of the United States, except for inventory purchases, a significant portion of which are primarily transacted in U.S. dollars from vendors in the United States. The local currency of each of our Subsidiaries' primary markets is considered the functional currency with the exception of our Asia product-distribution subsidiary in Singapore. All revenue and expenses are translated at weighted-average exchange rates for the periods reported. Therefore, our reported revenue and earnings will be positively impacted by a weakening of the U.S. dollar and will be negatively impacted by a strengthening of the U.S. dollar. Given the large portion of our business derived from outside of the United States, any strengthening of the U.S. dollar negatively impacts reported revenue and profits, whereas a weakening of the U.S. dollar positively impacts our reported revenue and profits. Given the uncertainty of exchange rate fluctuations, it is difficult to predict the effect of these fluctuations on our future business, product pricing and results of operations or financial condition. During 2015 and 2016, the strengthening of the U.S. dollar against other currencies significantly impacted our financial results.

Additionally, we may seek to reduce our exposure to fluctuations in foreign currency exchange rates through the use of foreign currency exchange contracts and through intercompany loans of foreign currency. We do not use derivative financial instruments for trading or speculative purposes. We regularly monitor our foreign currency risks and periodically take measures to reduce the impact of foreign exchange fluctuations on our operating results. As of March 31, 2017, we did not hold any non-designated mark-to-market forward derivative contracts to hedge foreign-currency-denominated intercompany positions or third-party foreign debt. As of March 31, 2016 we held non-designated mark-to-market forward derivative contracts to hedge foreign-currency-denominated intercompany positions or third-party foreign debt with notional amounts of 5.8 billion South Korean won and 500 million Japanese yen (\$5.0 million and \$4.4 million, respectively, as of March 31, 2016). Gains and losses related to non-designated derivative contracts are recorded as part of Other Income (Expense). In addition, as of March 31, 2017, we held forward contracts designated as foreign currency cash flow hedges with notional amounts totaling approximately 2.3 billion Japanese yen (\$20.6 million) to hedge forecasted foreign-currency-denominated intercompany transactions, compared to 3.9 billion Japanese yen and 12.0 million euros (\$34.6 million and \$13.7 million, respectively, as of March 31, 2016) as of March 31, 2016. Because of our foreign exchange contracts at March 31, 2017, the impact of a 10% appreciation or 10% depreciation of the U.S. dollar against the Japanese yen would not represent a material potential loss in fair value, earnings or cash flows against these contracts. This potential loss does not consider the underlying foreign currency transaction or translation exposures to which we are subject.

Non-GAAP Financial Measures

Regulation G, Conditions for Use of Non-GAAP Financial Measures, and other SEC regulations define and prescribe the conditions for use of certain non-GAAP financial information. Our measures of earnings per share, gross profit and net income, each excluding the Japan customs expense, meet the definition of non-GAAP financial measures. Earnings per share, gross profit and net income, each excluding the Japan customs expense, are used in addition to and in conjunction with results presented in accordance with GAAP and should not be relied upon to the exclusion of GAAP financial measures.

Management believes these non-GAAP financial measures assist management and investors in evaluating, and comparing from period to period, results from ongoing operations in a more meaningful and consistent manner while also highlighting more meaningful trends in the results of operations.

The following is a reconciliation of gross profit, as reported, to gross profit excluding Japan customs expense for the three months ended March 31, 2017 and 2016 (U.S. dollars in thousands):

	Quarter Ended March 31,			
	2	017	2	016
Revenue	\$	499,099	\$	471,831
Gross profit Japan customs expense Gross profit, excluding Japan customs expense	\$ 	387,833 — 387,833	\$ \$	333,962 31,355 365,317
Gross profit as a % of revenue	<u>-</u>	77.7%)	70.8%
Gross profit, excluding Japan customs expense, as a % of revenue		77.7%)	77.4%

The following is a reconciliation of net income and diluted earnings per share, as reported, to net income and diluted earnings per share excluding Japan customs expense for the three months ended March 31, 2017 and 2016 (U.S. dollars in thousands, except per share amounts):

Quarter Ended

	March 31,			
	20	17		2016
Net income	\$	27,489	\$	3,316
Japan customs expense		_		31,355
Tax effect of Japan customs expense		_		(11,257)
Net income, excluding Japan customs expense	\$	27,489	\$	23,414
Diluted earnings per share	\$	0.51	\$	0.06
Diluted earnings per share, excluding Japan customs expense	\$	0.51	\$	0.42
Diluted weighted-average common shares outstanding (000s)		54,057		56,411

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The information required by Item 3 of Part I of Form 10-Q is incorporated herein by reference from the section entitled "Currency Risk and Exchange Rate Information" in "Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations" of Part I and also from Note 4 to the consolidated financial statements contained in this report.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, under the supervision and with the participation of our management, including our Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO"), we evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")). Based on that evaluation, our CEO and our CFO concluded that our disclosure controls and procedures were effective as of March 31, 2017.

Changes in Internal Controls Over Financial Reporting.

We made no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) during the fiscal quarter ended March 31, 2017 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

The following information supplements and amends our discussion set forth under "Legal Proceedings" in our Annual Report on Form 10-K for the 2016 fiscal year. Except as discussed below, there have been no material developments concerning the matters discussed in that report.

In April 2017, the Tokyo High Court issued a ruling in our dispute with the customs authorities in Japan. The High Court affirmed the Tokyo District Court's February 2016 decision upholding previous customs assessments related to the importation of several of our products into Japan during 2010. The High Court's decision applies only to imports that occurred during 2010; our appeal regarding imports during the other time periods in the dispute is still pending with the High Court. We intend to appeal the High Court's decision to the Japan Supreme Court. As previously disclosed, we already recorded a charge of \$31.4 million to cost of sales in the first quarter of 2016, when the District Court issued its decision. This was a non-cash item because we were previously required to pay the assessments. This charge represents the full amount that was disputed, including assessments for the period of October 2006 through September 2009 in connection with post-importation audits, as well as the disputed portion of our import duties from October 2009 to the date of the District Court's decision.

From time to time, we are involved in other legal proceedings arising in the ordinary course of business. We believe that the resolution of these matters will not have a negative material effect on our consolidated financial position, results of operations or liquidity.

Please refer to Notes 11 and 15 to the consolidated financial statements contained in this report and to our discussion set forth under "Legal Proceedings" in our Annual Report on Form 10-K for the 2016 fiscal year for additional information regarding our legal proceedings.

ITEM 1A. RISK FACTORS

The information presented below supplements and should be read in conjunction with the detailed discussion of risks associated with our business in our recent SEC filings, including our Annual Report on Form 10-K for the 2016 fiscal year.

Improper sales force actions that violate laws or regulations could harm our business.

Sales force activities that violate applicable laws or regulations could result in government or third-party actions against us, which could harm our business.

For example, in 2014, allegations were made by various media outlets that certain of our sales representatives in Mainland China failed to adequately follow and enforce our policies and regulations. In response to these and other allegations, our Audit Committee commenced an internal review and Chinese regulators commenced a review of our business in Mainland China. In response to this media scrutiny and government review, we voluntarily took a number of actions in Mainland China, including temporarily suspending our business meetings, temporarily suspending acceptance of applications for any new sales representatives, and extending our product refund and return policies. The adverse publicity and suspension of business meetings and acceptance of applications had a significant negative impact on our revenue and the number of Sales Leaders and Customers in the region, and our business in Mainland China still has not fully recovered from these events. For example, as of December 31, 2016, we had approximately 22,000 Sales Leaders in Mainland China, compared to approximately 49,000 as of December 31, 2013. Similar or more extreme actions by government agencies in Mainland China in the future could have a significant adverse impact on our business and results of operations.

The direct selling industry in Japan continues to experience regulatory and media scrutiny, and other direct selling companies have been suspended from sponsoring activities in the past. Japan imposes strict requirements regarding how distributors approach prospective customers. Over the last few years, we have from time to time received warnings from regulatory agencies in certain prefectures about the number of general inquiries and complaints about us and our distributors. In 2013, we changed our distributor sign-up process in Japan and expanded our distributor compliance, education and training efforts in Japan to address concerns expressed by Japanese regulatory agencies. However, we cannot be certain that our efforts will successfully prevent regulatory actions against us, including fines, suspensions or other sanctions, or that the company and the direct selling industry will not receive further negative media attention, all of which could harm our business.

Except in Mainland China, members of our sales force are not employees and act independently of us. The most significant area of risk for such activities relates to improper product claims and claims regarding the business opportunity of joining our sales force. These risks associated with improper claims may increase as our sales force makes increased use of social selling channels. We implement strict policies and procedures to ensure our sales force complies with legal requirements. However, given the size of our sales force, we experience problems from time to time. For example, product claims made by some of our sales force in 1990 and 1991 led to a United States Federal Trade Commission ("FTC") investigation that resulted in our entering into a consent agreement with the FTC and various agreements with state regulatory agencies. In addition, rulings by the South Korean Federal Trade Commission and by judicial authorities against us and other companies in South Korea indicate that vicarious liability may be imposed on us for the criminal activity of our sales force. We have also seen an increase in the use of social media by our sales force, and an increase in sales aids and promotional material produced by our sales force in some markets, increasing the burden on us to monitor compliance of such materials, and increasing the risk that such materials could contain problematic claims in violation of our policies and applicable regulations. As we expand internationally, our sales force often attempts to anticipate which markets we will open in the future and begin marketing and sponsoring activities in markets where we are not qualified to conduct business. We could face fines, suspensions or other legal action if our sales force violates applicable laws and regulations, and our reputation and brand could be negatively impacted.

If we are unable to retain our existing sales force and recruit additional people to join our sales force, our revenue will not increase and may even decline.

Our products are primarily marketed by our sales force and we depend on them to generate virtually all of our revenue. Our sales force may terminate their services at any time, and like most direct selling companies, we experience relatively high turnover among our sales force from year to year. People who join our company to purchase our products for personal consumption or for short-term income goals frequently only stay with us for a short time. Sales Leaders who have committed time and effort to build a sales organization will generally stay for longer periods. Our sales force has highly variable levels of training, skills and capabilities. To increase our revenue, we must increase the number of and/or the productivity of our sales force.

We have experienced periodic declines in both Sales Leaders and Customers in the past and could experience such declines again in the future. Our ability to retain our Sales Leaders and Customers could be affected as our sales force makes increased use of social selling channels, which may allow them to more easily engage their consumers and sales network in other opportunities. If our initiatives do not drive growth in both Sales Leaders and Customers, our operating results could be harmed. While we take many steps to help train, motivate and retain our sales force, we cannot accurately predict how the number and productivity of our sales force may fluctuate because we rely primarily upon our Sales Leaders to find new consumers, and to find, train and develop new Sales Leaders. Our operating results could be harmed if we and our Sales Leaders do not generate sufficient interest in our business and its products to retain and motivate our existing sales force and attract new people to join our sales force.

The number and productivity of our sales force could be harmed by several additional factors, including:

- · any adverse publicity regarding us, our products, our distribution channel, or our competitors;
- lack of interest in, dissatisfaction with, or the technical failure of, existing or new products;
- lack of compelling products or income opportunities, including through our sales compensation plans;
- · any negative public perception of our products and their ingredients;
- any negative public perception of our sales force and direct selling businesses in general;
- our actions to enforce our policies and procedures;
- any regulatory actions or charges against us or others in our industry;
- general economic and business conditions;
- recruiting efforts of our competitors; and
- potential saturation or maturity levels in a given country or market which could negatively impact our ability to attract and retain our sales force in such market.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Recent Sales of Unregistered Securities

On February 28, 2017, we entered into an agreement to purchase a 35% interest in a manufacturing entity for cash and 169,560 shares of our Class A Common Stock. This sale was a privately negotiated transaction in reliance on Section 4(a)(2) of the Securities Act of 1933.

Period	(a) Total Number of Shares Purchased	Aver	(b) rage Price Paid per Share	(c) Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	M M	(d) Approximate Dollar Value of Shares that ay Yet Be Purchased Under the Plans or Programs (in millions)(1)
January 1 – 31, 2017 February 1 – 28, 2017 March 1 – 31, 2017 Total	136,917 136,917	\$ \$	49.76 49.76	136,917 136,917	\$ \$ \$	199.7 199.7 192.9

⁽¹⁾ In October 2015, we announced that our board of directors approved a stock repurchase plan. Under this plan, our board of directors authorized the repurchase of up to \$500.0 million of our outstanding Class A common stock on the open market or in privately negotiated transactions.

ITEM 3. **DEFAULTS UPON SENIOR SECURITIES**

None.

ITEM 4. **MINE SAFETY DISCLOSURES**

Not Applicable.

ITEM 5. **OTHER INFORMATION**

None.

EXHIBITS ITEM 6.

Regulation S-K Number	<u>Description</u>
3.1	Fourth Amended and Restated Bylaws of Nu Skin Enterprises, Inc. (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed March 10, 2017).
10.1	Employment Letter Agreement with Mark H. Lawrence (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed March 9, 2017).
10.2	Leave of Absence Agreement with M. Truman Hunt.
31.1	Certification by Ritch N. Wood, Chief Executive Officer, pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification by Mark H. Lawrence, Chief Financial Officer, pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1	Certification by Ritch N. Wood, Chief Executive Officer, pursuant to Section 1350, Chapter 63 of Title 18, United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	Certification by Mark H. Lawrence, Chief Financial Officer, pursuant to Section 1350, Chapter 63 of Title 18, United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document
	-32-

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

May 3, 2017

NU SKIN ENTERPRISES, INC.

By: /s/ Mark H. Lawrence

Mark H. Lawrence Chief Financial Officer

(Duly Authorized Officer and Principal Financial and Accounting Officer)

LEAVE OF ABSENCE AGREEMENT

This LEAVE OF ABSENCE AGREEMENT (this "Agreement") is entered into on April 24, 2017, by and among Nu Skin Enterprises, Inc., a Delaware corporation ("Company"), and Truman Hunt ("Employee").

RECITALS

- A. Employee has requested a special leave of absence in order to fulfill an ecclesiastical assignment for his church. It is anticipated that such special leave of absence would be for approximately three years.
- B. Company is willing to provide Employee with certain benefits during the special leave of absence in consideration of the restrictive covenants and release of claims. Company and Employee are entering into this Agreement in order to set forth the terms and conditions of such special leave of absence.

AGREEMENT

The parties hereby agree as follows:

- 1. <u>Leave of Absence</u>. Company hereby authorizes Employee to take a special leave of absence (the "Special Leave") in order to serve in a volunteer ecclesiastical assignment. Such Special Leave shall commence on July 1, 2017, and continue through September 30, 2020, unless terminated earlier pursuant to the provisions of Section 5 by either party. During the Special Leave, Employee authorizes Company to use Employee's name and likeness for Company's marketing and other purposes. Notwithstanding the foregoing, all compensation and benefits shall be terminated on July 1, 2017 (including the payment of any further salary) except for the benefits specifically identified and described in this Agreement. Employee shall be entitled to receive the cash incentive bonus for the 2nd quarterly incentive period of 2017 in accordance with Company's 2017 cash incentive plan and Employee's salary and target bonus percentage that are in effect for each of the quarterly periods. Employee shall also be entitled to receive a cash incentive bonus for the 2017 annual incentive period in accordance with Company's 2017 cash incentive plan and Employee's salary and target bonus percentage that are in effect for the first sixmonths of 2017; provided, however, that the bonus payment for the annual incentive period shall be reduced by 50% to reflect that Employee only provided service for six months during the annual incentive period.
- 2. <u>Special Leave Benefits</u>. Except to the extent prohibited by law or the express provisions of any employee benefit plan, during the Special Leave Company shall provide Employee with the benefits described in this Section 2 (the "Special Leave Benefits"). Other than the Special Leave Benefits, no other compensation or benefits shall be provided to or accrue to the benefit of Employee. Employee shall be responsible for any tax impact on Employee related to the Special Leave Benefits.

- a. <u>Health Insurance</u>. To the extent allowable under Company's group medical and dental plans, Company shall continue to provide coverage under these plans to Employee during the Special Leave. Employee shall remain liable to pay the employee portion of the insurance costs as established from time to time by Company for its employees. In lieu of coverage under Company's group medical and dental plans, Employee may elect to secure his own private insurance during the Special Leave. In such event, Company shall reimburse Employee for his documented out-of-pocket (and un-reimbursed) costs to acquire such insurance up to an amount equal to the amount Company would have paid (net of Employee's contribution) under Company's group plans to provide medical and/or dental insurance coverage to Employee.
- b. <u>Product Allotment</u>. During the Special Leave, Employee may receive (i) Company product from regular inventory having a cost of goods value of up to \$6,000 per year for personal use by Employee and his immediate family members; and (ii) an unlimited amount of Company product from Company's employee store for personal use by Employee and his immediate family members. Employee may also use the product for personal gifts in accordance with Company's policies.
- c. Equity. With respect to the equity awards that have been granted to Employee under Company's equity incentive plans and the applicable award agreements, except as provided in paragraph d. below, (i) notwithstanding anything in this Agreement to the contrary, for purposes of Employee's equity awards, Employee will be deemed to have voluntarily terminated his employment in connection with this Special Leave and Employee's "Continuous Service" shall be deemed terminated immediately prior to the commencement of this Special Leave, (ii) all unvested equity awards shall immediately terminate upon such termination of Employee's "Continuous Service," and (iii) all vested equity awards shall terminate in accordance with the terms of the individual equity awards with respect to the termination of awards upon termination of "Continuous Service" (e.g., if an award provides that vested options shall terminate 90 days after termination of "Continuous Service", the vested options for such award would terminate 90 days following the last day of "Continuous Service").
- d. 2016 Performance Equity Award. With respect to the performance stock option granted to Employee on March 2, 2016, (i) the third tranche of options which are scheduled to vest based on Company's earnings per share in 2018 shall terminate in full upon the commencement of the Special Leave; (ii) the Performance Stock Option Agreement applicable to such grant is hereby amended to provide that the second tranche of options scheduled to vest based on Company's earnings per share in 2017 shall remain outstanding, subject to the terms of the Performance Stock Option Agreement, and shall vest in accordance with the vesting schedule for such tranche of options set forth in the Performance Stock Option Agreement and the earnings per share certified by the Executive Compensation Committee; provided, however, the amount of options that may vest shall be reduced by 50% to reflect that Employee only provided service for 50% of the performance period; (iii) and any options that do not vest in accordance with paragraph d.(ii) shall immediately terminate upon certification by the Executive Compensation Committee of the earnings per share for 2017; (iv) the options that vested in the first tranche based on 2016 performance shall terminate in accordance with the original terms of the Performance Stock Option Agreement with respect to the termination of awards upon termination of "Continuous Employment" (i.e., three years from the commencement of the Leave of Absence); and (v) any options in the second tranche that vest pursuant to paragraph d.(ii) above, shall terminate on May 31, 2018.

- e. <u>Deferred Compensation Plan</u>. Employee shall be considered to remain in the employment of the Company during the Special Leave to the extent permitted under applicable law with respect to the Company's deferred compensation plan; provided, however, that Company shall not provide any contributions to the Deferred Compensation other than those contributions tied specifically to employment during the first six months of 2017.
- f. <u>Life Insurance</u>. During the Special Leave, Company shall continue to pay the premiums for \$750,000 in term life insurance coverage for Employee.
- g. <u>Health Savings Account</u>. During the Special Leave, Company shall contribute \$1,200 per year into Employee's health savings account to the extent Employee remains eligible for such contribution.
- 3. <u>Key Employee Covenants</u>. All key-employee covenants that are applicable to Employee shall remain in full force and effect during the Special Leave period except for the non-non-competition covenant and the non-solicitation covenant which shall be superseded by the provisions of this Section 3.
 - Non-Compete. In consideration for the compensation payable pursuant to this Agreement, Employee agrees that, during this Special Leave, Employee shall not, directly or indirectly, in any market where Company or subsidiaries engage in business: (i) engage in any Competitive Business; (ii) undertake to plan or organize any Competitive Entity; (iii) become associated or connected in any way with, participate in, be employed by, render services to, or consult with, any Competing Entity (nor shall the Employee discuss the possibility of employment or other relationship with any Competing Entity); or (iv) own any direct or indirect interest in any other Competing Entity; provided, however, this limitation shall not be interpreted as prohibiting Employee from investing in a Competing Entity that is a public company so long as such investment does not exceed 1% of the outstanding securities of such public company and Employee discloses in writing to the Company (a) the name of the public company and the number of shares which he owns, and (b) any material change in the Employee's ownership. This Section 3.a shall not restrict the right of the Employee to practice law in violation of any applicable rules of professional conduct. For purposes of this Section 3, "Competitive Business" shall mean the (i) multi-level marketing channel through which products and services are marketed directly to consumers through a sales force of independent contractors (including, without limitation, through person to person contact, via the telephone, video or through the Internet) who receive rewards or commissions based upon a compensation plan which contemplates a genealogical sales force of multiple levels, with such commissions paid for by (A) sales of products and services by such contractor, and/or (B) sales of products and services by other independent contractors in such contractor's genealogical downline, and (ii) a home-based business opportunity focused on selling products directly to the consumers. For purposes of his Section 3, "Competing Entity" shall mean any entity or person that is engaged, directly or indirectly, in a Competitive Business.

- b. Employee shall not in any way, directly or indirectly, at any time during this Special Leave or within two years following termination of this Special Leave: (a) recruit, solicit or sponsor any customer, or distributor or other member of Company's sales force, to terminate their relationship with the Company or to form a relationship with, promote, sell or purchase the products or services of, participate as a salesperson of, or otherwise associate with, a Competing Entity; (b) recruit or solicit any distributor or other member of Company's sales force, employee, vendor, consultant or other person or entity in the employment or service of Company or any of its respective subsidiaries or affiliates at the time of such solicitation, in any case to (i) terminate such employment or service, and/or (ii) accept employment, or enter into any consulting or other service arrangement, with any person or entity other than Company or any of its respective subsidiaries or affiliates; or (c) assist any other person in any attempt to do any of the foregoing.
- 4. <u>No Guaranty of Employment</u>. Employee shall not be guaranteed employment or any position with Company following the termination or expiration of the Special Leave.
- 5. <u>Termination</u>. This Special Leave may be terminated at any time by Employee upon a written notice to Company for any reason or no reason. This Special Leave may be terminated at any time by the Company upon written notice to Employee for any reason or no reason. Upon termination of the Special Leave by Employee or Company, the Company shall have no further obligation to provide the Special Leave Benefits. In addition, Employee shall remain subject to those key employee covenants that by their terms survive the termination of employment.
- 6. <u>Release of Claims</u>. In consideration of the benefits provided under this Agreement, Employee, on behalf of himself and all persons and entities claiming by, through, or under Employee, hereby completely releases Company and all shareholders, agents, directors, executives and employees of Company from all claims, charges, demands, grievances, and/or causes of action that Employee had, has, or may claim to have based on, arising from, or relating to Employee's employment with Company or the termination thereof, including, without limitation, any claims, charges, demands, grievances, and/or causes of action under:
 - a. Title VII of the Civil Rights Acts of 1964 and 1991, as amended, which prohibit discrimination on the basis of race, color, sex, religion, or national origin;
 - b. Section 1981 of the Civil Rights Act of 1866, which prohibits discrimination on the basis of race;

- c. The Employee Retirement Income Security Act as of the effective date of this Agreement;
- d. Any state laws against discrimination; or
- e. Any other federal, state, or local statute or common law relating to employment.

The foregoing release also includes, without limitation, release of any claims for wrongful discharge, breach of express or implied contract of employment, employment-related torts, personal injury (whether physical or mental), or any other claims in any way related to Employee's employment with or termination of employment with Company. Employee acknowledges and agrees that Employee has not been discriminated against in any manner prohibited by law during Employee's employment with Company or with regard to the termination of Employee's employment with Company.

Notwithstanding the foregoing, Employee does not waive any rights to (i) unemployment insurance benefits or worker's compensation benefits, (ii) any benefits accrued, vested, or otherwise available to Employee under the 401(k) plan, Employee's Health Savings Account, the Deferred Compensation Plan, and the equity award agreements under the 2010 Omnibus Incentive Plan or its amendments (subject in all respects to the provisions of this Agreement), (iii) any indemnification rights under Company's charter documents or the indemnification agreement entered into between Company and Employee, (iv) any insurance policy insuring officers and directors of Company, (v) any claims that cannot be waived under applicable law, and (vi) any claims for a breach by Company of this Agreement. Employee further understands that nothing in this release prohibits Employee from paying COBRA premiums to maintain Employee's participation in Company's group health plan to the extent allowed by law and subject to the terms, conditions, and limitations set forth in Company's group health plan.

Employee acknowledges that Employee is waiving and releasing any rights Employee may have under the Age Discrimination in Employment Act of 1967 ("ADEA") and that this waiver and release is knowing and voluntary. Employee and Company agree that this waiver and release does not apply to any rights or claims that may arise under ADEA after the effective date of this Agreement. Employee acknowledges that the consideration given for this waiver and release agreement is in addition to anything of value to which Employee was already entitled. Employee further acknowledges that Employee has been advised by this writing that:

- (i) Employee should consult with an attorney prior to executing this Agreement;
- (ii) Employee has at least 21 days within which to consider this Agreement, although Employee may accept the terms of this Agreement at any time within those 21 days;
- (iii)Employee has at least seven days following the execution of this Agreement by the parties to revoke this Agreement; and
- (iv) This Agreement will not be effective until the revocation period has expired.

Employee acknowledges that	Company does not have a	formal leave of absence r	oolicy and that Company	has no obligation to al	low a leave of absence
THIDIOVEE ACKNOWIEUSES HIAL	Company does not have a	i iniliai icave ni ansciice i	JULICY alla ulai Cullibaliy	mas no obneauon to ai	TOM WIEGAL OF SPETICE

- 7. Tax Acknowledgment. Employee represents and acknowledges that he has consulted with his tax advisors regarding the tax consequences of the benefits and other provisions of this Agreement and that Employee is not relying on any tax advice from Company in entering into this Agreement or determining how to treat the benefits under this Agreement for tax purposes. Employee acknowledges that Section 409A and the regulations promulgated thereunder are new and complex and that there are significant penalties associated with failure to properly defer income. Employee represents and acknowledges he has been advised to seek advice from his own tax advisors with respect to Section 409A issues associated with this Agreement and the benefits being provided hereunder. Employee shall be responsible for any and all taxes associated with the benefits provided above including any penalties or interest resulting from failure to properly recognize such income for income tax purposes.
- 8. <u>Severability</u>. If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any law or public policy, all other terms and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner materially adverse to any party.
- 9. <u>Governing Law.</u> The validity of this Agreement and the interpretation and performance of all of its terms shall be governed by the substantive and procedural laws of the State of Utah. Each party expressly submits and consents to exclusive personal jurisdiction and venue in the courts of Utah County, State of Utah or in any Federal District Court in Utah.
- 10. Entire Agreement. This Agreement, along with the documents expressly referenced in this Agreement, including the Key Employee Covenants and equity incentive plans and grant documents, constitute the entire agreement between the parties. No other promises or agreements have been made to Employee or Company other than those contained in this Agreement. Employee and Company acknowledge that they have read this agreement carefully, fully understand the meaning of the terms of this Agreement, and are signing this Agreement knowingly and voluntarily. This Agreement may not be modified except by an instrument in writing signed by all of the parties hereto.

[Signature Page follows]

IN WITNESS WHEREOF, the parties hereto have executed this Agreement on the dates indicated below.

/s/ Ritch N. Wood	4/24/17
Ritch Wood	Date
Chief Executive Officer	
EMPLOYEE	
/s/ Truman Hunt	4/24/17
Truman Hunt	Date

[Signature Page to Truman Hunt Leave of Absence Agreement]

NU SKIN ENTERPRISES, INC.

EXHIBIT 31.1 SECTION 302 – CERTIFICATION OF CHIEF EXECUTIVE OFFICER

I, Ritch N. Wood, certify that:

- 1. I have reviewed this quarterly report on Form 10-Q of Nu Skin Enterprises, Inc.;
- 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- 4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
- (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
- (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
- (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
- (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
- (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
- (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 3, 2017 /s/Ritch N. Wood
Ritch N. Wood

Chief Executive Officer

EXHIBIT 31.2 SECTION 302 – CERTIFICATION OF CHIEF FINANCIAL OFFICER

I, Mark H. Lawrence, certify that:

- 1. I have reviewed this quarterly report on Form 10-Q of Nu Skin Enterprises, Inc.;
- 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- 4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
- (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
- (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
- (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
- (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
- (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
- (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 3, 2017 /s/ Mark H. Lawrence
Mark H. Lawrence
Chief Financial Officer

EXHIBIT 32.1 SECTION 906 CERTIFICATION OF CHIEF EXECUTIVE OFFICER

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Nu Skin Enterprises, Inc. (the "Company") on Form 10-Q for the period ended March 31, 2017 (the "Report"), I, Ritch N. Wood, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

- 1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 3, 2017

/s/ Ritch N. Wood Ritch N. Wood Chief Executive Officer

EXHIBIT 32.2 SECTION 906 CERTIFICATION OF CHIEF FINANCIAL OFFICER

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Nu Skin Enterprises, Inc. (the "Company") on Form 10-Q for the period ended March 31, 2017 (the "Report"), I, Mark H. Lawrence, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

- 1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 3, 2017

/s/ Mark H. Lawrence Mark H. Lawrence Chief Financial Officer